FDA standards--good enough for government work?
Avorn
Jerry
J
Harvard Medical School, Boston, USA.
D002186:Cannabinoids / Q000037:antagonists & inhibitors; D020372:Dexfenfluramine / Q000009:adverse effects / Q000627:therapeutic use; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D006801:Humans; D009765:Obesity / Q000188:drug therapy; D010880:Piperidines / Q000009:adverse effects; D011720:Pyrazoles / Q000009:adverse effects; D000077285:Rimonabant; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence / Q000592:standards*
D002186:Cannabinoids; D010880:Piperidines; D011720:Pyrazoles; D020372:Dexfenfluramine; D000077285:Rimonabant